Armistice Capital LLC lessened its holdings in shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Free Report) by 72.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,750 shares of the company’s stock after selling 61,250 shares during the quarter. Armistice Capital LLC owned 3.81% of Salarius Pharmaceuticals worth $54,000 as of its most recent SEC filing.
Salarius Pharmaceuticals Stock Performance
Salarius Pharmaceuticals stock opened at $1.44 on Friday. The firm’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $3.00. The firm has a market capitalization of $856,695.00, a price-to-earnings ratio of -0.07 and a beta of 0.95. Salarius Pharmaceuticals, Inc. has a 1-year low of $1.35 and a 1-year high of $7.60.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last released its quarterly earnings results on Friday, August 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($53.60) by $51.23. On average, research analysts forecast that Salarius Pharmaceuticals, Inc. will post -214.4 EPS for the current year.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Read More
- Five stocks we like better than Salarius Pharmaceuticals
- Quiet Period Expirations Explained
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- What Is WallStreetBets and What Stocks Are They Targeting?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What is a Dividend King?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding SLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Free Report).
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.